Nelson Vergel
Founder, ExcelMale.com
Unity Biotechnology announced on October 27 it raised $116 million in financing from a group of investors including Amazon CEO Jeff Bezos and the Mayo Clinic's venture capital arm.
Unity's early work is focusing on cellular senescence to help treat aging-related diseases. This biological process is an important mechanism that prevents the proliferation of potential cancer cells and could play a role in promoting tissue repair and fuel inflammation, according to the Journal of Cell Biology.
The company published a study in Nature explaining that selectively eliminating senescent cells could treat atherosclerosis, which is a condition that entails a build-up of fats and cholesterols in the walls of heart arteries impeding blood flow.
http://www.dddmag.com/article/2016/...t_cid=5654441&et_rid=449166332&linkid=content
Unity's early work is focusing on cellular senescence to help treat aging-related diseases. This biological process is an important mechanism that prevents the proliferation of potential cancer cells and could play a role in promoting tissue repair and fuel inflammation, according to the Journal of Cell Biology.
The company published a study in Nature explaining that selectively eliminating senescent cells could treat atherosclerosis, which is a condition that entails a build-up of fats and cholesterols in the walls of heart arteries impeding blood flow.
http://www.dddmag.com/article/2016/...t_cid=5654441&et_rid=449166332&linkid=content
